Angel Biotechnology said that the contract, for process development and GMP manufacture of specific antibodies, is valued at circa GBP1.3m. Work on the project is expected to start shortly and GMP manufacturing is expected to complete in early 2012.
Gordon Sherriff, chief operating officer of Angel Biotechnology, said: “Angel has provided effective support to Materia Medica’s medicinal product development program over the last three years.
“We are very pleased that this biopharmaceutical company has awarded Angel a further GMP manufacturing contract, demonstrating the strength of our working relationship. We look forward to continued allegiance with Materia Medica.”
Sergey Tarasov, from R&D department of Materia Medica, said: “We look forward to a continued mutually beneficial collaboration with Angel for advancing our medicinal product portfolio. Based on our positive working experience with Angel, we are committed to the company being Materia Medica’s long term GMP manufacturing partner.”